![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BST1 |
Gene summary for BST1 |
![]() |
Gene information | Species | Human | Gene symbol | BST1 | Gene ID | 683 |
Gene name | bone marrow stromal cell antigen 1 | |
Gene Alias | CD157 | |
Cytomap | 4p15.32 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q10588 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
683 | BST1 | LZE7T | Human | Esophagus | ESCC | 4.05e-05 | 2.99e-01 | 0.0667 |
683 | BST1 | LZE8T | Human | Esophagus | ESCC | 2.62e-04 | 2.35e-01 | 0.067 |
683 | BST1 | P5T-E | Human | Esophagus | ESCC | 9.35e-10 | 2.15e-01 | 0.1327 |
683 | BST1 | P12T-E | Human | Esophagus | ESCC | 8.73e-28 | 5.45e-01 | 0.1122 |
683 | BST1 | P20T-E | Human | Esophagus | ESCC | 3.83e-03 | 4.92e-02 | 0.1124 |
683 | BST1 | P27T-E | Human | Esophagus | ESCC | 3.90e-42 | 8.35e-01 | 0.1055 |
683 | BST1 | P54T-E | Human | Esophagus | ESCC | 9.95e-03 | 1.78e-01 | 0.0975 |
683 | BST1 | P74T-E | Human | Esophagus | ESCC | 4.96e-09 | 3.38e-01 | 0.1479 |
683 | BST1 | P107T-E | Human | Esophagus | ESCC | 3.29e-02 | 9.63e-02 | 0.171 |
683 | BST1 | P130T-E | Human | Esophagus | ESCC | 5.68e-24 | 4.80e-01 | 0.1676 |
683 | BST1 | ATC12 | Human | Thyroid | ATC | 1.15e-03 | 1.03e-01 | 0.34 |
683 | BST1 | ATC13 | Human | Thyroid | ATC | 7.27e-33 | 7.18e-01 | 0.34 |
683 | BST1 | ATC2 | Human | Thyroid | ATC | 1.60e-07 | 5.32e-01 | 0.34 |
683 | BST1 | ATC4 | Human | Thyroid | ATC | 1.97e-05 | 1.34e-01 | 0.34 |
683 | BST1 | ATC5 | Human | Thyroid | ATC | 5.50e-43 | 7.94e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
GO:000195217 | Esophagus | ESCC | regulation of cell-matrix adhesion | 85/8552 | 128/18723 | 1.70e-06 | 2.02e-05 | 85 |
GO:000716018 | Esophagus | ESCC | cell-matrix adhesion | 141/8552 | 233/18723 | 3.33e-06 | 3.71e-05 | 141 |
GO:200037718 | Esophagus | ESCC | regulation of reactive oxygen species metabolic process | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
GO:00072299 | Esophagus | ESCC | integrin-mediated signaling pathway | 67/8552 | 107/18723 | 3.03e-04 | 1.81e-03 | 67 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:00507303 | Esophagus | ESCC | regulation of peptidyl-tyrosine phosphorylation | 144/8552 | 264/18723 | 2.22e-03 | 9.78e-03 | 144 |
GO:000268515 | Esophagus | ESCC | regulation of leukocyte migration | 114/8552 | 210/18723 | 7.26e-03 | 2.63e-02 | 114 |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:0032970210 | Thyroid | ATC | regulation of actin filament-based process | 208/6293 | 397/18723 | 5.82e-15 | 3.80e-13 | 208 |
GO:0032956210 | Thyroid | ATC | regulation of actin cytoskeleton organization | 190/6293 | 358/18723 | 1.73e-14 | 1.01e-12 | 190 |
GO:001081029 | Thyroid | ATC | regulation of cell-substrate adhesion | 128/6293 | 221/18723 | 8.74e-14 | 4.57e-12 | 128 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:0001952110 | Thyroid | ATC | regulation of cell-matrix adhesion | 78/6293 | 128/18723 | 2.09e-10 | 6.15e-09 | 78 |
GO:000722919 | Thyroid | ATC | integrin-mediated signaling pathway | 63/6293 | 107/18723 | 7.09e-08 | 1.24e-06 | 63 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BST1 | SNV | Missense_Mutation | rs779256447 | c.667N>A | p.Glu223Lys | p.E223K | Q10588 | protein_coding | tolerated(0.09) | possibly_damaging(0.891) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BST1 | SNV | Missense_Mutation | c.765C>G | p.Phe255Leu | p.F255L | Q10588 | protein_coding | tolerated(0.08) | possibly_damaging(0.72) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BST1 | SNV | Missense_Mutation | rs113632818 | c.662N>A | p.Arg221Gln | p.R221Q | Q10588 | protein_coding | tolerated(0.36) | benign(0.113) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
BST1 | SNV | Missense_Mutation | c.423G>C | p.Leu141Phe | p.L141F | Q10588 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
BST1 | SNV | Missense_Mutation | rs752630803 | c.26N>G | p.Ser9Trp | p.S9W | Q10588 | protein_coding | tolerated(0.11) | benign(0.157) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BST1 | SNV | Missense_Mutation | rs375412643 | c.457G>A | p.Asp153Asn | p.D153N | Q10588 | protein_coding | tolerated(0.58) | probably_damaging(0.995) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BST1 | SNV | Missense_Mutation | rs765296526 | c.551N>A | p.Ser184Tyr | p.S184Y | Q10588 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
BST1 | SNV | Missense_Mutation | rs2302466 | c.230C>T | p.Ala77Val | p.A77V | Q10588 | protein_coding | tolerated(0.64) | benign(0) | TCGA-AF-6672-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Ancillary | leucovorin | PD |
BST1 | insertion | Frame_Shift_Ins | rs761650390 | c.612-1_612insT | p.Ala207CysfsTer4 | p.A207Cfs*4 | Q10588 | protein_coding | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
BST1 | deletion | Frame_Shift_Del | c.655delA | p.Ile219LeufsTer25 | p.I219Lfs*25 | Q10588 | protein_coding | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
683 | BST1 | DRUGGABLE GENOME | Beta blocking agents, selective |
Page: 1 |